The Impact of Addition of Consolidation Chemotherapy to Standard Cisplatin-Based Chemoradiotherapy in Uterine Cervical Cancer: Matter of Distant Relapse
Table 1
Clinical characteristics of the patients.
Characteristic
Freq. (%)
Consolidation CT
No Consolidation CT
p
Number of patients
58 (31.2)
128 (68.8)
Age (median/IQR)
41.5 (34.5 – 54.5)
51.3 (41.7 – 63.0)
< 0.0001
ECOG performance status
0
36 (62.1)
81 (64.8)
0.720
≥ 1
22 (37.9)
44 (35.2)
Histology
Squamous cell carcinoma
41 (70.7)
98 (79.0)
0.217
Adenocarcinoma
17 (29.3)
26 (21.0)
Grade
1 and 2
34 (77.3)
59 (60.8)
0.056
3
10 (22.7)
38 (39.2)
FIGO stage
0.637
IB2
3 (5.2)
7 (5.5)
IIA2
2 (3.4)
5 (3.9)
IIB
26 (44.8)
62 (48.8)
IIIA
2 (3.4)
4 (3.1)
IIIB
15 (25.9)
36 (28.3)
IVA
9 (15.5)
7 (5.5)
IVB
1 (1.7)
5 (3.9)
Tumor size
< 6cm
28 (75.7)
56 (76.7)
0.904
≥ 6cm
9 (24.3)
17 (23.3)
Lymph node
Negative
25 (43.1)
55 (46.2)
0.732
Pelvic
32 (55.2)
60 (50.4)
Paraaortic
1 (1.7)
4 (3.4)
Concurrent CT < 6 cycles
No
46 (79.3)
75 (64.7)
0.048
Yes
12 (20.7)
41 (35.3)
Radiotherapy technique
3D
53 (91.4)
88 (71.0)
0.002
2D
5 (8.6)
36 (29.0)
Brachytherapy
No
3 (5.2)
15 (12.0)
0.149
Yes
55 (94.8)
110 (88.0)
All p values calculated using Chi square test or Fisher’s exact test. CT = chemotherapy. IQR = Interquartile Range. Paraaortic lymph nodes only.
